You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 10, September 14, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Men's Health
 •Prostate Disease
 •Oncology
 •Prostate Cancer
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Localized Prostate Cancer and DNA Ploidy

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their study of the long-term outcomes following conservative management of localized prostate cancer, Dr Albertsen and colleagues1 conclude that a Gleason score of 2 to 4 is a very good prognostic sign. However, the Gleason score is a highly subjective measure that is based on a pathologists’ perception of tissue patterns. A much more objective prognostic measure is the DNA content or ploidy of tumor cells.2-3

Carcinomas with normal, near-normal, or diploid DNA content are less aggressive and less likely to extend beyond the prostate than nondiploid (aneuploid) cancers.3-4 As recently suggested by Lorenzato et al,5 therapeutic decisions that depend on the extent of prostate cancer (organ-confined T1T2 or non–organ-confined T3T4) can be helped by DNA analysis of the tumor, potentially reducing the rate of unnecessary radical prostatectomy with its attendant adverse effects of incontinence and impotence. For example, in patients with prostate-specific antigen levels of . . . [Full Text of this Article]

Leopold G. Koss, MD
lkoss@montefiore.org
Montefiore Medical Center
Bronx, NY



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Localized Prostate Cancer and DNA Ploidy—Reply
Peter C. Albertsen, James A. Hanley, and Judith Fine
JAMA. 2005;294(10):1207-1208.
EXTRACT | FULL TEXT  

20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Peter C. Albertsen, James A. Hanley, and Judith Fine
JAMA. 2005;293(17):2095-2101.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.